SCHEMBL13290959

SCHEMBL13290959

COC1CCN(C(=O)[C@H]2CC[C@H](C(=O)Nc3c(C(=O)Nc4ccc(Cl)cn4)oc4cccnc34)CC2)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.43
▸ F10 P00742 5/20 0.41
▸ MEN1 O00255 4/20 0.38
▸ KMT2A Q03164 4/20 0.38
▸ HSD17B10 Q99714 3/20 0.38
▸ TSHR P16473 3/20 0.38
▸ MAPT P10636 2/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ RAB9A P51151 3/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ DHODH Q02127 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ MALT1 Q9UDY8 1/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ TP53 P04637 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13290946 0.89 SMN1; SMN2 (0.43) SMN1; SMN2F10MEN1KMT2ATSHR
SCHEMBL13290953 0.89 SMN1; SMN2 (0.43) SMN1; SMN2F10MEN1KMT2ATSHR
SCHEMBL13290955 0.88 SMN1; SMN2 (0.44) SMN1; SMN2F10MEN1KMT2ATSHR
SCHEMBL2945024 0.87 SMN1; SMN2 (0.46) SMN1; SMN2F10MEN1KMT2ATSHR
SCHEMBL2945028 0.87 SMN1; SMN2 (0.46) SMN1; SMN2F10MEN1KMT2ATSHR
SCHEMBL13290954 0.87 SMN1; SMN2 (0.46) SMN1; SMN2F10MEN1KMT2ATSHR
SCHEMBL13290769 0.86 SMN1; SMN2 (0.44) SMN1; SMN2F10MEN1KMT2ATSHR
SCHEMBL13879657 0.83 F10 (0.47) SMN1; SMN2F10MEN1KMT2ATSHR
SCHEMBL2950971 0.83 SMN1; SMN2 (0.48) SMN1; SMN2F10MEN1KMT2AHSD17B10
SCHEMBL2950956 0.83 SMN1; SMN2 (0.48) SMN1; SMN2F10MEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-7737161-B2 Condensed furan compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-06-15 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-20090156803-A1 Condensed furan compounds KAWAGUCHI TAKAYUKI 2009-06-18 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed
US-7514449-B2 Fused furan compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156803-A1 Condensed furan compounds F2, F12, F11 SMN1; SMN2 4447/4885F10 4/4885MEN1 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback